SiBone (NASDAQ:SIBN) CFO Sells $91,791.70 in Stock

SiBone (NASDAQ:SIBN - Get Free Report) CFO Anshul Maheshwari sold 5,005 shares of the company's stock in a transaction that occurred on Wednesday, July 2nd. The stock was sold at an average price of $18.34, for a total value of $91,791.70. Following the sale, the chief financial officer owned 217,078 shares in the company, valued at approximately $3,981,210.52. This represents a 2.25% decrease in their position. The sale was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this hyperlink.

Anshul Maheshwari also recently made the following trade(s):

• On Monday, May 19th, Anshul Maheshwari sold 2,424 shares of SiBone stock. The shares were sold at an average price of $19.48, for a total value of $47,219.52.
• On Friday, May 16th, Anshul Maheshwari sold 9,585 shares of SiBone stock. The stock was sold at an average price of $19.76, for a total value of $189,399.60.
• On Monday, May 12th, Anshul Maheshwari sold 4,937 shares of SiBone stock. The stock was sold at an average price of $19.02, for a total value of $93,901.74.
• On Wednesday, May 7th, Anshul Maheshwari sold 4,937 shares of SiBone stock. The shares were sold at an average price of $17.00, for a total value of $83,929.00.

SiBone Stock Up 0.9%

NASDAQ SIBN traded up $0.17 on Tuesday, reaching $18.19. The company had a trading volume of 104,192 shares, compared to its average volume of 394,055. The stock has a market capitalization of $775.26 million, a P/E ratio of -28.42 and a beta of 0.93. The company's fifty day moving average is $17.89 and its 200 day moving average is $16.23. SiBone has a 52-week low of $11.70 and a 52-week high of $20.05. The company has a quick ratio of 7.26, a current ratio of 8.53 and a debt-to-equity ratio of 0.21.

SiBone (NASDAQ:SIBN - Get Free Report) last announced its quarterly earnings data on Monday, May 5th. The company reported ($0.15) earnings per share (EPS) for the quarter, beating analysts' consensus estimates of ($0.24) by $0.09. The firm had revenue of $47.29 million during the quarter, compared to the consensus estimate of $45.13 million. SiBone had a negative return on equity of 16.00% and a negative net margin of 15.03%. Sell-side analysts anticipate that SiBone will post -0.78 earnings per share for the current fiscal year.

Hedge Funds Weigh In On SiBone

Large investors have recently modified their holdings of the company. ANTIPODES PARTNERS Ltd bought a new position in SiBone during the 1st quarter worth approximately $34,000. Virtus Fund Advisers LLC bought a new position in SiBone during the 4th quarter worth approximately $40,000. GAMMA Investing LLC grew its position in SiBone by 20,352.6% during the 1st quarter. GAMMA Investing LLC now owns 3,886 shares of the company's stock worth $55,000 after acquiring an additional 3,867 shares during the last quarter. Virtus Advisers LLC bought a new position in SiBone during the 1st quarter worth approximately $58,000. Finally, KLP Kapitalforvaltning AS bought a new position in SiBone during the 4th quarter worth approximately $97,000. 98.11% of the stock is owned by hedge funds and other institutional investors.

Wall Street Analyst Weigh In

Several analysts recently weighed in on the company. Truist Financial raised their price objective on SiBone from $20.00 to $22.00 and gave the company a "buy" rating in a research note on Tuesday, May 6th. Needham & Company LLC restated a "buy" rating and set a $24.00 price target on shares of SiBone in a report on Tuesday, May 6th. Finally, Cantor Fitzgerald restated an "overweight" rating and set a $25.00 price target on shares of SiBone in a report on Tuesday, May 6th.

About SiBone

SI-BONE, Inc, a medical device company, that operate to solve musculoskeletal disorders of the sacropelvic anatomy in the United States and internationally. It offers proprietary minimally invasive surgical implant system to address sacroiliac joint dysfunction and fusion, adult deformity and degeneration, and pelvic trauma; and implantable bone products.